Ori Biotech and Vineti collaborate on digital platform for CGTs

This partnership follows on from Ori’s $30 m Series A funding round in 2020, and Vineti’s release of its PTM Essentials solution for advanced therapy clinical trials

Ori Biotech and Vineti are partnering to produce an integrated solution to streamline the manufacture and delivery of cell and gene therapies (CGTs).

Ori provides a proprietary platform that incorporates automation and digitalisation of production data. It works with companies across the cell and gene therapy industry to integrate and secure the product journey. Vineti’s personalised therapy management (PTM) platform is a digital solution for advanced therapy data and supply chains. The companies will combine their platforms to deliver a system that aims to support therapies from clinical-phase to commercial distribution at scale.

“The pre-integration of Vineti’s Chain of Identity and Chain of Custody systems with the Ori full-stack platform is critical to help ensure our customers have full end-to-end visibility, control, and insights into their processes,” said Ori Biotech CEO Jason C. Foster. “The addition of established technologies in such a critical aspect of CGT manufacturing allows us to enable our partners across the industry to develop and commercialise therapies as safely, cost effectively, and quickly as possible to reach the large numbers of patients who need these therapeutic alternatives.”

“Advanced therapies are at a point where they require true industrialisation, with the best digital tools and a connected ecosystem,” said Vineti CEO and Co-founder Amy DuRoss. “We’re very excited to partner with Ori Biotech to deliver our shared next-generation vision and ultimately help breakthrough treatments get to patients faster.”

Companies